Basil Kadhim Abdullah Al Odda1*, Zardasht Bakr Mohammed2, Dashti Latif Muhe Alddina2, Zainab Basil Kadhim Al Odda3, Ghada Basil Kadhim Al Odda4, Ali Omer Qadir2, Rebwar Ahmed Shrif2, Ghazi Ali Fakrealdeen5 and Khenda Muhammed Abdullah6
1Department of Pediatrics, Hiwa Teaching Hospital, Iraq 2Department of Pediatric Hematology, Hiwa Teaching Hospital, Iraq 3Amman University, Jordan 4Freshta Secondary School, Iraq 5Department of Pediatric Oncology, Hiwa Teaching Hospital, Iraq 6Department of Pediatric Hematology and Oncology, Hiwa Teaching Hospital, IraqFulltext PDF
Patient with Down syndrome (trisomy 21) have more than 10 time increasing risk Of acute leukemia with more than 1% of children with down syndrome will develop Acute Myeloid Leukemia (AML), this increase risk occur primarily in children with Down Syndrome (DS) under the age of 10 years. Among patients with DS, AML most commonly occur between 1 to 4 years old age, megakaryocytic AML (M7) which is uncommon subtype of AML mostly affecting patients with DS. We reported a patient with Down syndrome who developed AML M2 (Myeloblastic without maturation) at the age of 2 years who was treated by single agent low dose Cytarabine (Ara-C) chemotherapy because of associated cardiac comorbidity for 24 months, currently she is 4 years off chemotherapy and on complete remission.
Down syndrome; Trisomy 21; Acute myeloid leukemia; Low dose chemotherapy; Atrioventricular Septal Defect (AVSD)
Al Odda BKA, Mohammed ZB, Alddina DLM, Al Odda ZBK, Al Odda GBK, Qadir AO, et al. Low Dose Single Agent Chemotherapy Cured a Child with Down Syndrome and Acute Myeloid Leukemia. Clin Oncol. 2020; 5: 1748..